ArticleInvestigative ophthalmology & visual science2025
Scutellarin Protects Retinal Ganglion Cells in Glaucoma by Targeting the Hsp90aa1-MAPK Pathway to Inhibit Apoptosis.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Neurotoxic effects of dietary glutamate in glaucoma and potential nutritional and pharmacological therapies: a scoping review.International ophthalmology · 2026Article
- Targeting CRBN With Thalidomide Suppresses Fibrosis After Glaucoma Drainage Surgery Through NF-κB Pathway Inhibition.Investigative ophthalmology & visual science · 2026Article
- Scutellarin attenuates high glucose-induced edema and inflammation in retinal Müller cells via AQP4/Kir4.1 restoration and TLR4/MyD88/NF-κB inhibition.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Glaucoma, a major cause of irreversible blindness, is characterized by progressive retinal ganglion cells (RGCs) degeneration. Existing treatments can merely delay disease progression, failing to prevent RGC loss or visual field defects. For the management of ophthalmic diseases, Scutellarin (Scu) has demonstrated neuroprotective potential, but its efficacy and mechanisms in glaucoma remain unexplored. This study aims to evaluate the neuroprotective role of Scu in glaucoma and to reveal its underlying mechanisms. Methods: Cell viability was assessed using CCK-8 and Hoechst 33342/propidium iodide staining. RGC damage and visual function were evaluated via flash visual evoked potential, immunofluorescence and hematoxylin-eosin staining. The potential targets and pathways were identified by network pharmacology, whereas the Scu-target binding affinity was evaluated by molecular docking and cellular thermal shift assay. Expression of key genes was silenced using siRNA, and protein levels were analyzed by Western blotting. Results: Scu significantly mitigated the damage in a glutamate-induced retinal excitotoxicity glaucoma model. Network pharmacology and molecular docking identified Hsp90AA1 as a key target. Kyoto Encyclopedia of Genes and Genomes analysis associated the protective effects of Scu with the MAPK pathway, which was further supported by GO analysis that highlights its role in apoptosis regulation. Overall, Scu was found to mitigate apoptosis by modulating the Hsp90aa1-MAPK pathway, evidenced by the fact that Hsp90aa1 knockdown abolished the protective effects of Scu. Conclusions: Scu exerts neuroprotective effects in glaucoma by targeting the Hsp90aa1-MAPK pathway, thereby suppressing apoptosis. This offers a potential therapeutic strategy for glaucoma management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.